We are live on ! Find out more
ORKA icon

Oruka Therapeutics
ORKA

12 hedge funds and large institutions have $910K invested in Oruka Therapeutics in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 12 → 12 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

7.67% less ownership

Funds ownership: 19.34% → 11.67% (-7.7%)

78% less capital inflows, than outflows

Capital inflows: $208K | Capital outflows: $954K

Holders
12
Holders Change
–
Holders Change %
0%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$120K
2
ARTA
A.R.T. Advisors
New York
+$85.9K
3
Victory Capital Management
Victory Capital Management
Texas
+$1.47K
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$147

Top Sellers

Rank Fund Capital Flow
1
Aveo Capital Partners
Aveo Capital Partners
Colorado
-$661K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$263K
3
Quantamental Technologies
Quantamental Technologies
New York
-$16.8K
4
UBS Group
UBS Group
Switzerland
-$13K

ORKA Hedge Fund Activity: Q3 2019 in Review

12 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2019, worth a combined $910K — down 54% from $1.96M a quarter earlier.

Fund positioning in ORKA was balanced in Q3 2019: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $120K. The largest seller was Aveo Capital Partners, exiting entirely with an estimated $661K sold.

  • 12 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $910K of Oruka Therapeutics stock for Q3 2019, down 54% quarter-over-quarter.
  • 3 funds opened new Oruka Therapeutics positions in Q3 2019 and 3 closed out, a net change of 0 holders.
  • The largest Oruka Therapeutics buyer in Q3 2019 was Renaissance Technologies, an estimated $120K added.
  • The largest Oruka Therapeutics seller in Q3 2019 was Aveo Capital Partners, an estimated $661K sold.

Based on aggregated 13F filings for Q3 2019.